Stem Cells for Uremic Calciphylaxis Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Calcific Uremic Arteriolopathy
- Calciphylaxis
- Chronic Kidney Diseases
- Treatment
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 60 years
- Gender
- Both males and females
Description
Calciphylaxis is a rare, devastating disorder causing excruciatingly painful ischemic skin lesions. Sepsis due to the infection of ulcerated wounds is a common cause of death. To date, practical therapies typically include wound care, pain management, anti-infection and aggressive treatment of predi...
Calciphylaxis is a rare, devastating disorder causing excruciatingly painful ischemic skin lesions. Sepsis due to the infection of ulcerated wounds is a common cause of death. To date, practical therapies typically include wound care, pain management, anti-infection and aggressive treatment of predisposing conditions. Drugs such as sodium thiosulfate, bisphosphonate, and cinacalcet are also suggested. However, it's still a lethal disease with 1-year mortality up to 80% for dialysis patients. Here the investigators plan to treat uremic calciphylaxis patients with human amniotic mesenchymal stem cells (hAMSCs).
Tracking Information
- NCT #
- NCT04592640
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Ningning Wang, Professor The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital Study Director: Jiayin Liu, Professor The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital Principal Investigator: Lianju Qin The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Get Well Soon